Arctic Bioscience - Mandatory notification of trade

18 Oct 2024 20:15 CEST

Eggesbø Eiendom AS, a legal person closely associated with a person discharging
managerial responsibility in Arctic Bioscience, has today sold 520,240 shares in
Arctic Bioscience at an average price of NOK 2,23 per share. Following the
transaction, Eggesbø Eiendom AS holds 0 shares in Arctic Bioscience.

Member of the Board at Arctic Bioscience, Per Magne Eggesbø, is the chairman of
the board and CEO of Eggesbø Eiendom AS, and owns 21% of the company.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

629927_20241018_Appendix_3_Notifying_Transactions_Eggesbo_Eiendom_AS.pdf